Koninklijke Philips N.V.

Koninklijke Philips N.V. Earnings Recaps

PHG Health Care 2 recaps
Next earnings: February 9, 2027 (estimated) · full calendar
Q3 2026 Nov 5, 2026

Philips shares rose 12.6% after earnings, as investors rewarded a 70-basis-point adjusted EBITA margin increase to 13%, ahead of management’s expectations, alongside 8% order intake growth. The full-year outlook was reiterated; sales growth was more modest at approximately 3%, with Diagnosis & Treatment broadly flat and Connected Care orders down mid-single digit.

Key takeaways
  • Comparable sales grew approximately 3% in Q3, led by Personal Health and Connected Care; Personal Health grew 8%.
  • Order intake increased 8%, including nearly 20% growth in Diagnosis & Treatment. Equipment order intake also grew 8%, and the equipment order book rose sequentially and year on year.
  • Adjusted EBITA margin expanded 70 basis points to 13%; free cash flow was an inflow of EUR 384 million.
  • Connected Care order intake declined mid-single digit against a high prior-year comparison, with some major orders shifting into Q4. Diagnosis & Treatment sales were broadly flat, reflecting ultrasound shipment timing and lower sales in China.
  • Philips recorded a EUR 288 million provision related to the agreement in principle with the U.S. Department of Justice concerning Respironics. The company reiterated its full-year outlook.
Q1 2026 May 7, 2026

Philips shares gained modestly (+2.7%) following a quarter that largely met expectations, supported by steady order intake and margin expansion, though market reaction suggests investors were cautious on incremental upside.

Key takeaways
  • Order intake rose 6%, driven by strength in North America and disciplined growth across Diagnostic & Therapeutic (D&T) and Connected Care segments.
  • Comparable sales increased 4% with broad-based growth in Personal Health and sustained momentum in key imaging modalities such as MRI and CT.
  • Adjusted EBITDA margin expanded by 40 basis points to 9%, despite inflationary pressures including higher tariffs.
  • Innovation momentum continued with 20 FDA clearances/pre-market approvals, notably delivering AI-enabled solutions in cardiac MRI, spectral CT, and image-guided therapy.
  • Management reiterated full-year guidance reflecting confidence in execution amidst ongoing macro uncertainty, but the market’s tempered response implies vigilance on competitive and geopolitical risks.